ABO-incompatible living donor transplantation: Is it economically "compatible"?

Transplantation

Volumn 82, Issue 2, 2006, Pages 168-169

  Schnitzler, Mark ^a   MacHnicki, Gerardo ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Cost effective; Organ donation; Reimbursement

Indexed keywords

CD20 ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

BLOOD GROUP ABO INCOMPATIBILITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MEDICARE; NOTE; PLASMAPHERESIS; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; COST OF ILLNESS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; RENAL DIALYSIS; UNITED STATES;

EID: 33746435721     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000226242.10027.e7     Document Type: Note

References (18)

1. Montgomery RA. ABO incompatible transplantation: To B or not to B? Am J Transplant 2004; 4: 1011.
2. Crew RJ, Ratner LE. Overcoming immunologic incompatibility: transplanting the difficult to transplant patient. Semin Dial 2005; 18: 474.
3. Magee CC. Transplantation across previously incompatible immunological barriers. Transpl Int 2006; 19: 87.
4. Schwartz J, Stegall MD, Kremers WK, Gloor J. Complications, resource utilization and cost of ABO incompatible living donor kidney transplantation. Transplantation 2006; 82: 154.
5. Eggers P. Comparison of treatment costs between dialysis and transplantation. Semin Nephrol 1992; 12(3): 284.
6. Mutinga N, Brennan D, Schnitzler MA. Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation. Am J Transplant 2005; 5: 1090.
7. Schnitzler MA, Lentine KL, Burroughs TE. The cost effectiveness of deceased organ donation. Transplantation 2005; 80(11): 1636.
8. Schnitzler MA, Whiting JF, Brennan DC, et al. The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 2003; 75(12): 1940.
9. Loubeau PR, Loubeau JM, Jantzen R. The economics of kidney transplantation versus hemodialysis. Prog Transplant 2001; 11 (4): 291.
10. Simon DG. A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. Med Decis Making 1986; 6(4): 199.
11. Hornberger JC, Best JH, Garrison LP, Jr. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997; 17: 363.
12. Yen EF, Hardinger K, Brennan DC, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004; 4(10): 1703.
13. Matas AJ, Schnitzler M. Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. Am J Transplant 2004; 4(2): 216.
14. Eichler H-G, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health care resource allocation decision making: How are cost-effectiveness thresholds expected to emerge? Value in Health 2004; 7(5): 518.
15. Evans RW. The private sector vis-a-vis government in future funding of organ transplantation. Transplant Proc 1990; 22(3): 975.
16. Evans RW. Cost containment and managed care in liver transplantation. Acta Gastroenterol Belg 1999; 62(3): 363.
17. Evans RW, Kitzmann DJ. Contracting for services: liver transplantation in the era of mismanaged care. Clin Liver Dis 1997; 1(2): 287-303.
18. Evans RW. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. Clin Transpl 1993: 359.